September 16, 2016 10:03 AM EDTUpdated September 18, 11:43 PM
R&D

No­vo’s big re­veal: GLP-1 drug semaglu­tide cuts car­dio risks, but just may blind you

John Carroll

Editor & Founder

First, the good news for No­vo Nordisk’s di­a­betes drug semaglu­tide: The drug re­duced the num­ber of ma­jor car­dio events by 26% among high-risk pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times